Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to assess the safety, tolerability, and pharmacokinetics of two
clinical doses of the anti-orthopoxvirus drug, ST-246, administered as a single daily oral
dose for 14 days to healthy, fed volunteers. The results of this trial determine which dose
will be used in expanded pivotal safety trials.